Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of M605110 short-contact therapy in acne vulgaris
jRCT2031220333Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of M605110 in acne vulgaris, sponsored by Maruho Co., Ltd. Primary endpoint: Percentage change in total lesion count. Started Sep 2022; status: completed.
02
Drugs
M605110
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on jRCT2031220333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220333.